Avoid common mistakes on your manuscript.
Correction to: Adv Ther https://doi.org/10.1007/s12325-021-01716-8
In the original article, Figure 1 was published incorrectly. The correct Fig. 1 is given below.
Recurrent VTE or VTE-related death, major bleeding, and composite of major or CRNM bleeding during the treatment period by body weight category. CI confidence interval, CRNM clinically relevant non-major, NE not estimable, RR relative risk, VTE venous thromboembolism
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Cohen, A.T., Pan, S., Byon, W. et al. Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. Adv Ther 38, 4596–4597 (2021). https://doi.org/10.1007/s12325-021-01822-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-021-01822-7